Nanobiotix (NASDAQ:NBTX) Sees Unusually-High Trading Volume - Here's Why

Key Points

• Nanobiotix (NASDAQ:NBTX) experienced a significant increase in trading volume, with 54,178 shares changing hands, marking a 122% rise compared to the previous session.
• Analysts have a mixed view on NBTX, with a consensus "Hold" rating and a target price of $11.00, though Weiss Ratings has a "sell" rating while HC Wainwright maintains a "buy" rating.
• The stock has recently appreciated 9.6%, with institutional investors now owning 38.81% of the company following a new position acquired by Millennium Management LLC.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report) saw an uptick in trading volume on Thursday . 54,178 shares changed hands during trading, an increase of 122% from the previous session's volume of 24,408 shares.The stock last traded at $27.11 and had previously closed at $27.30.

Analyst Ratings Changes

Several research analysts have weighed in on NBTX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a research note on Wednesday. Leerink Partners set a $14.00 target price on Nanobiotix in a research note on Thursday, September 18th. Finally, HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $11.00.

Nanobiotix Stock Up 9.6%

The firm has a fifty day moving average price of $11.29 and a 200 day moving average price of $6.66.

Hedge Funds Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Millennium Management LLC acquired a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,452 shares of the company's stock, valued at approximately $39,000. Institutional investors and hedge funds own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.